Emerging Role of Circulating Tumor Cells in Gastric Cancer

Cancers

Sanjeev Gurshaney¹  HungD. Nguyen¹  Phung Thanh Huong²  Carlo La Vecchia³  Claudio Pelucchi³  HungN. Luu⁴  Nhuong Xuan Duong⁵  Khanh Truong Vu⁶  Phuong-Thao Tran⁷  Hai Pham-The⁷  Nguyen Thanh Binh⁸  Anh Gia Pham⁹  Huy Hoang Nguyen⁹  Xuan Thanh Nguyen⁹  Paolo Boffetta^1,10 

[1] Cancer Division, Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA;Department of Biochemistry, Hanoi University of Pharmacy, Hanoi 10000, Vietnam;Department of Clinical, Sciences and Community Health, University of Milan, 20133 Milan, Italy;Department of Epidemiology, University of Pittsburg Graduate School of Public Health, Pittsburg, PA 15261, USA;Department of Gastroenterology, 103 Hospital, Hanoi 10000, Vietnam;Department of Gastroenterology, Bach Mai Hospital, Hanoi 10000, Vietnam;Department of Pharmaceutical Chemistry, Hanoi University of Pharmacy, Hanoi 10000, Vietnam;Department of Pharmaceutical Management and Economics, Hanoi University of Pharmacy, Hanoi 10000, Vietnam;Department of Surgical Oncology, Viet-Duc University Hospital, Hanoi 10000, Vietnam;Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Division of Hematology and Medical Oncology, New York, NY 10029, USA;

关键词: circulating tumor cells;    gastric cancer;    diagnostic;    prognostic;    treatment;   

DOI  :  10.3390/cancers12030695

来源: DOAJ

【 摘 要 】

With over 1 million incidence cases and more than 780,000 deaths in 2018, gastric cancer (GC) was ranked as the 5th most common cancer and the 3rd leading cause of cancer deaths worldwide. Though several biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4), have been identified, their diagnostic accuracies were modest. Circulating tumor cells (CTCs), cells derived from tumors and present in body fluids, have recently emerged as promising biomarkers, diagnostically and prognostically, of cancers, including GC. In this review, we present the landscape of CTCs from migration, to the presence in circulation, biologic properties, and morphologic heterogeneities. We evaluated clinical implications of CTCs in GC patients, including diagnosis, prognosis, and therapeutic management, as well as their application in immunotherapy. On the one hand, major challenges in using CTCs in GC were analyzed, from the differences of cut-off values of CTC positivity, to techniques used for sampling, storage conditions, and CTC molecular markers, as well as the unavailability of relevant enrichment and detection techniques. On the other hand, we discussed future perspectives of using CTCs in GC management and research, including the use of circulating tumor microembolies; of CTC checkpoint blockade in immunotherapy; and of organoid models. Despite the fact that there are remaining challenges in techniques, CTCs have potential as novel biomarkers and/or a non-invasive method for diagnostics, prognostics, and treatment monitoring of GC, particularly in the era of precision medicine.

【 授权许可】

Unknown